StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly mounjaro — Worldwide revenue growth YoY (%) (%)

Form 10-Q / 10-K MD&A & Form 8-K Releases

Latest, Q2 2026
91.0%
Period ended Jun 30, 2026
Change on a year earlier
+23.0 pts
68.0% in Q2 2025
History
12 quarters
Since Q2 2023
Sources
12
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMounjaro — Worldwide revenue growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202691.0%+23.0 ptsForm 10-Q FY2026Q2 (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026125.0%+12.0 ptsForm 10-Q FY2026Q1 (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025110.0%+50.0 ptsEarnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗
Q3 2025Sep 30, 2025109.0%-23.4 ptsForm 10-Q FY2025Q3 (filed 2025-10-30) ↗
Q2 2025Jun 30, 202568.0%+4.0 ptsForm 10-Q FY2025Q2 (filed 2025-08-07) ↗
Q1 2025Mar 31, 2025113.0%+81.0 ptsForm 10-Q FY2025Q1 (filed 2025-05-01) ↗
Q4 2024Dec 31, 202460.0%–Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗
Q3 2024Sep 30, 2024132.4%+42.4 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q2 2024Jun 30, 202464.0%+60.6 ptsForm 10-Q FY2024Q2 (filed 2024-08-08) ↗
Q1 2024Mar 31, 202432.0%–Form 10-Q FY2024Q1 (filed 2024-04-30) ↗
Q3 2023Sep 30, 202390.0%–Form 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q2 2023Jun 30, 20233.4%–Form 10-Q FY2023Q2 (filed 2023-08-08) ↗

Cite this data

StockData. (2026). Eli Lilly Mounjaro — Worldwide revenue growth YoY (%) (%), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_mounjaro_yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.